Literature DB >> 20843689

A retro-inverso TAT-like peptide designed to deliver cysteamine to cells.

Jongdoo Lim1, Jean-Philippe Pellois, Eric E Simanek.   

Abstract

A retro-inverso, TAT-like peptide wherein lysine residues are replaced with cysteine residues bearing a disulfide-linked cysteamine group is found to engage in thiol-disulfide exchange with cysteine. These peptides are transported into cells and localize to lysosomes. Cellular uptake is enhanced in peptides bearing two cysteamine groups over those with one or none, by factors of approximately 1.5 and 12, respectively.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20843689      PMCID： PMC3881279          DOI： 10.1016/j.bmcl.2010.07.046

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  17 in total

Review 1.  The design, synthesis and application of stereochemical and directional peptide isomers: a critical review.

Authors:  P M Fischer
Journal:  Curr Protein Pept Sci       Date:  2003-10       Impact factor: 3.272

2.  Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion.

Authors:  Meredith C Fidler; Bruce A Barshop; Jon A Gangoiti; Reena Deutsch; Michael Martin; Jerry A Schneider; Ranjan Dohil
Journal:  Br J Clin Pharmacol       Date:  2007-01       Impact factor: 4.335

Review 3.  Molecular and cellular basis of lysosomal transmembrane protein dysfunction.

Authors:  Raquel Ruivo; Christine Anne; Corinne Sagné; Bruno Gasnier
Journal:  Biochim Biophys Acta       Date:  2008-12-24

4.  Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein.

Authors:  M Green; P M Loewenstein
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

Review 5.  Cystinosis: a review.

Authors:  J A Schneider; J D Schulman
Journal:  Metabolism       Date:  1977-07       Impact factor: 8.694

Review 6.  Pharmacological treatment of nephropathic cystinosis with cysteamine.

Authors:  Robert Kleta; William A Gahl
Journal:  Expert Opin Pharmacother       Date:  2004-11       Impact factor: 3.889

7.  The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters.

Authors:  P A Wender; D J Mitchell; K Pattabiraman; E T Pelkey; L Steinman; J B Rothbard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

Review 8.  Current and emerging therapies for the lysosomal storage disorders.

Authors:  Gregory M Pastores; Natalie L Barnett
Journal:  Expert Opin Emerg Drugs       Date:  2005-11       Impact factor: 4.191

9.  A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis.

Authors:  L A Smolin; K F Clark; J G Thoene; W A Gahl; J A Schneider
Journal:  Pediatr Res       Date:  1988-06       Impact factor: 3.756

Review 10.  Recent advances in the treatment of cystinosis.

Authors:  J A Schneider; K F Clark; A A Greene; J S Reisch; T C Markello; W A Gahl; J G Thoene; P K Noonan; K A Berry
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.